Clinical trials: Optic Glioma, open to volunteers
High-Grade Glioma (WHO III-IV)
FG001 Near-Infrared Fluorescence Imaging During Tumor Resection in Newly Diagnosed High-Grade Glioma
This clinical trial aims to determine if FG001 can assist surgeons in identifying the difference between tumor and healthy tissue during surgery in participants with newly diagnosed high-grade glioma.
- Trial name
- NCT07609472
- Testing
- FG001
- Where
- 5 sites in United States
- Volunteers
- 76 people
- Sponsor
- FluoGuide A/S
Meningioma, Glioblastoma
Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical Procedures
This pilot clinical study evaluates the safety and imaging performance of panitumumab-IRDye800 (pan800), a fluorescent, EGFR-targeted imaging agent - in patients undergoing neurosurgical resection of intracranial lesions.
- Conditions
- Meningioma, Glioblastoma, Acoustic Neuroma, Brain Cancer
- Trial name
- NCT07493447
- Testing
- Panitumumab-IRDye800
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Eben Rosenthal
Glioblastoma Multiforme, Anaplastic Astrocytoma
Loupe-Based Intraoperative Fluorescence Imaging
Glioblastoma multiforme (GBM) and anaplastic astrocytoma (AA) are the most common primary malignant brain tumors. Survival of patients with these brain tumors is directly related to the extent of resection.
- Trial name
- NCT04780009
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Guoqiang Yu
Astrocytoma, Ependymoma
Proton Therapy Research Infrastructure- ProTRAIT- Neuro-oncology
The first proton therapy treatments in the Netherlands have taken place in 2018. Due to the physical properties of protons, proton therapy has tremendous potential to reduce the radiation dose to the healthy, tumour-surrounding…
- Conditions
- Astrocytoma, Ependymoma, Ganglioglioma, Oligodendroglioma
- Trial name
- NCT04648462
- Testing
- ProTRAIT
- Where
- 3 sites in Netherlands
- Volunteers
- 1,500 people
- Sponsor
- Maastricht Radiation Oncology
Malignant Brain Neoplasm, Malignant Glioma
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
The phase I/II trial studies the side effects and best dose of panitumumab-IRDye800 in diagnosing participants with malignant glioma who undergo surgery.
- Trial name
- NCT03510208
- Testing
- Near-Infrared Fluorescence Imaging, Panitumumab, Panitumumab-IRDye800
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Stanford University